| Project/Area Number |
26430163
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Tumor therapeutics
|
|---|
| Research Institution | Okayama University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
木浦 勝行 岡山大学, 大学病院, 教授 (10243502)
|
|---|
| Research Collaborator |
Kato Yuka 岡山大学, 大学院 病態制御科学 血液・腫瘍・呼吸器内科学
Tamura Tomoki 岡山大学, 大学院 病態制御科学 血液・腫瘍・呼吸器内科学
Ninomiya Kiichiro 岡山大学, 大学院 病態制御科学 血液・腫瘍・呼吸器内科学
Ohashi Kadoaki 岡山大学病院, 呼吸器・アレルギー内科
|
|---|
| Project Period (FY) |
2014-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2016: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2014: ¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
|
|---|
| Keywords | 肺癌 / EGFR / IL-6 / チロシンキナーゼ阻害薬 / EGFR遺伝子変異陽性非小細胞肺がん / EGFR-TKI / インターロイキン6（IL-6） |
|---|
| Outline of Final Research Achievements |
In our study, in 52 patients with EGFR-mutat lung cancer who received gefitinib, EGFR tyrosine kinase inhibitor (TKI), the high IL-6 expression group, accouting for 46%, tended to have poor progression-free survival as compared with the low expression group. In pre-clinical studies using cell lines, the efficacy of EGFR tyrosine kinase inhibitor was related to IL-6 expression level. Thus, EGFR-TKI treatment alone seems insufficient in the high IL-6 expression group, and further treatment strategy should be developed.
|
